These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12223071)

  • 1. Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque.
    Suckling KE; Macphee CH
    Expert Opin Ther Targets; 2002 Jun; 6(3):309-14. PubMed ID: 12223071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions.
    Häkkinen T; Luoma JS; Hiltunen MO; Macphee CH; Milliner KJ; Patel L; Rice SQ; Tew DG; Karkola K; Ylä-Herttuala S
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2909-17. PubMed ID: 10591668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
    Tselepis AD; John Chapman M
    Atheroscler Suppl; 2002 Dec; 3(4):57-68. PubMed ID: 12573364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk].
    Ferri N; Corsini A
    G Ital Cardiol (Rome); 2014 Dec; 15(12):664-9. PubMed ID: 25533115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments with lipoprotein-associated phospholipase A2 inhibitors.
    Chauffe RJ; Wilensky RL; Mohler ER
    Curr Atheroscler Rep; 2010 Jan; 12(1):43-7. PubMed ID: 20425270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.
    Rosenson RS; Stafforini DM
    J Lipid Res; 2012 Sep; 53(9):1767-82. PubMed ID: 22665167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis.
    Zalewski A; Macphee C; Nelson JJ
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):527-32. PubMed ID: 16503872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.
    Tellis CC; Tselepis AD
    Biochim Biophys Acta; 2009 May; 1791(5):327-38. PubMed ID: 19272461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein-associated phospholipase A2 as a target of therapy.
    Macphee CH; Nelson JJ; Zalewski A
    Curr Opin Lipidol; 2005 Aug; 16(4):442-6. PubMed ID: 15990594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipoprotein-associated phospholipase A2: importance and perspectives].
    Camici M
    Minerva Med; 2004 Apr; 95(2):133-42. PubMed ID: 15272248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein.
    Davis B; Koster G; Douet LJ; Scigelova M; Woffendin G; Ward JM; Smith A; Humphries J; Burnand KG; Macphee CH; Postle AD
    J Biol Chem; 2008 Mar; 283(10):6428-37. PubMed ID: 18165686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease.
    Caslake MJ; Packard CJ
    Curr Opin Lipidol; 2003 Aug; 14(4):347-52. PubMed ID: 12865731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.
    Karabina SA; Elisaf M; Bairaktari E; Tzallas C; Siamopoulos KC; Tselepis AD
    Eur J Clin Invest; 1997 Jul; 27(7):595-602. PubMed ID: 9263748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular phospholipases in atherosclerosis.
    Karabina SA; Gora S; Atout R; Ninio E
    Biochimie; 2010 Jun; 92(6):594-600. PubMed ID: 20153800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients.
    Ishihara M; Iwasaki T; Nagano M; Ishii J; Takano M; Kujiraoka T; Tsuji M; Hattori H; Emi M
    J Hum Genet; 2004; 49(6):302-307. PubMed ID: 15148590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.
    Caslake MJ; Packard CJ
    Nat Clin Pract Cardiovasc Med; 2005 Oct; 2(10):529-35. PubMed ID: 16186851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target.
    Macphee CH; Nelson J; Zalewski A
    Curr Opin Pharmacol; 2006 Apr; 6(2):154-61. PubMed ID: 16495153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target.
    Macphee CH
    Curr Opin Pharmacol; 2001 Apr; 1(2):121-5. PubMed ID: 11714085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease.
    Caslake MJ; Packard CJ; Suckling KE; Holmes SD; Chamberlain P; Macphee CH
    Atherosclerosis; 2000 Jun; 150(2):413-9. PubMed ID: 10856534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy.
    Leach CA; Hickey DM; Ife RJ; Macphee CH; Smith SA; Tew DG
    Farmaco; 2001; 56(1-2):45-50. PubMed ID: 11347966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.